Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced its management will participate in investor conferences including UBS Global Biopharma, Jefferies Global Healthcare, and Piper Sandler Annual Healthcare between November 17 and December 2, 2026. These events will feature live webcast fireside chats accessible on Nurix's website. The company focuses on developing treatments for cancer and autoimmune diseases, collaborating with Roche, Gilead, Sanofi, and Pfizer. These presentations provide Nurix an opportunity to update investors on its clinical progress and pipeline advancements.
Nurix Therapeutics' upcoming participation in investor conferences provides context for readers following biopharmaceutical developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced US health-sector stocks, 85 rose and 56 fell. Notable movers include MRVI at USD 7.83 with a 1-day change of -2.37%, ABEO at USD 2.60 with a 1-day change of +2.36% and a Pluang order activity of 29% Sell / 71% Buy, and DFTX at USD 36.18 with a 1-day change of +2.23% and 0% Sell / 100% Buy order activity on Pluang.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
